Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR inhibitor-naive

Advanced or metastatic disease EGFR inhibitor-naive

Non-small cell lung cancer · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Amivantamab Variant #01	EGFR	R 598 573	21d	8.9 mo	—	13	R 7 781 447 PFS proxy	2
Lazertinib and Amivantamab Variant #01 Partial	EGFR	R 426 311	28d	23.7 mo	—	26	R 11 084 073 PFS proxy	2
Osimertinib monotherapy Variant #01	EGFR	R 77 777	28d	16.6 mo	38.1 mo	19	R 1 477 762 PFS proxy	13
Erlotinib and Ramucirumab Variant #01	EGFR	R 67 170	14d	19.4 mo	—	43	R 2 888 292 PFS proxy	1
Carboplatin, Osimertinib, Pemetrexed Variant #01	EGFR	R 60 071	21d	8.4 mo	47.5 mo	13	R 780 921 PFS proxy	3
Cisplatin, Osimertinib, Pemetrexed Variant #01	EGFR	R 59 420	21d	8.4 mo	47.5 mo	13	R 772 464 PFS proxy	3
Erlotinib and Bevacizumab Variant #01	EGFR	R 52 071	28d	16.7 mo	49.1 mo	19	R 989 353 PFS proxy	6
Afatinib monotherapy Variant #01	EGFR	R 34 727	28d	11.0 mo	—	12	R 416 729 PFS proxy	4
Cisplatin and Gemcitabine (GC) Variant #34	EGFR	R 15 338	56d	5.6 mo	15.2 mo	4	R 61 352 PFS proxy	3
Erlotinib monotherapy Variant #01	EGFR	R 13 907	28d	10.2 mo	39.0 mo	12	R 166 883 PFS proxy	17
Carboplatin and Gemcitabine/Erlotinib Variant #01	EGFR	R 11 532	28d	7.6 mo	18.3 mo	9	R 103 791 PFS proxy	2
Cisplatin and Gemcitabine/Erlotinib Variant #01	EGFR	R 10 882	28d	7.6 mo	18.3 mo	9	R 97 936 PFS proxy	2
Gefitinib monotherapy Variant #01	EGFR	R 8 556	28d	10.2 mo	31.8 mo	12	R 102 667 PFS proxy	19
Apatinib and Gefitinib Variant #01 Partial	EGFR	R 8 556	28d	13.7 mo	—	15	R 128 333 PFS proxy	1
GCP Variant #01	EGFR	R 8 155	21d	16.0 mo	50.9 mo	24	R 195 716 PFS proxy	3
Gefitinib and Pemetrexed Variant #01	EGFR	R 7 129	21d	15.8 mo	—	23	R 163 972 PFS proxy	—
Carboplatin and Paclitaxel (CP) Variant #38	EGFR	R 5 031	21d	5.4 mo	—	8	R 40 246 PFS proxy	1
Anlotinib and Gefitinib Variant #01 Partial	EGFR	R 4 278	21d	14.8 mo	—	22	R 94 111 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	EGFR	R 3 663	21d	5.2 mo	15.2 mo	8	R 29 304 PFS proxy	4
Carboplatin and Docetaxel (DCb) Variant #01	EGFR	R 3 300	21d	5.2 mo	—	8	R 26 401 PFS proxy	1
Cisplatin and Pemetrexed Variant #01	EGFR	R 1 088	21d	5.5 mo	22.5 mo	8	R 8 701 PFS proxy	20
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	EGFR	R 449	21d	5.8 mo	—	9	R 4 043 PFS proxy	2
Carboplatin and Pemetrexed N/A - secondary systemic drug	EGFR	R 52	21d	5.6 mo	22.5 mo	9	R 469 PFS proxy	18
Furmonertinib monotherapy Variant #01 Partial	EGFR	—	28d	20.8 mo	—	23	—	1
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	12.5 mo	—	14	—	2
Dacomitinib monotherapy Variant #01 Partial	EGFR	—	28d	2.9 mo	34.1 mo	4	—	4
Aumolertinib monotherapy Variant #01 Partial	EGFR	—	28d	19.3 mo	—	21	—	1
Lazertinib monotherapy Variant #01 Partial	EGFR	—	28d	20.6 mo	—	23	—	1

28 of 28 regimens shown